Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 119

    1.

    Trends in lipid management among patients with coronary artery disease: has diabetes received the attention it deserves?

    Massing MW, Foley KA, Sueta CA, Chowdhury M, Biggs DP, Alexander CM, Simpson RJ Jr.

    Diabetes Care. 2003 Apr;26(4):991-7.PMID: 12663562 [PubMed - indexed for MEDLINE]Related articlesFree article

    2.

    Trends in lipid management among patients with diabetes.

    Tunceli K, Pladevall M, Williams LK, Divine GW, Simpkins JC, Nag SS, Sajjan SG, Kamal-Bahl SJ, Alexander CM, Lafata JE.

    Endocr Pract. 2006 Jul-Aug;12(4):380-7.PMID: 16901793 [PubMed - indexed for MEDLINE]Related articles

    3.

    LDL-C goal attainment among patients newly diagnosed with coronary heart disease or diabetes in a commercial HMO.

    Nag SS, Daniel GW, Bullano MF, Kamal-Bahl S, Sajjan SG, Hu H, Alexander C.

    J Manag Care Pharm. 2007 Oct;13(8):652-63.PMID: 17970603 [PubMed - indexed for MEDLINE]Related articlesFree article

    5.

    Mixed dyslipidemia among patients using lipid-lowering therapy in French general practice: an observational study.

    Van Ganse E, Laforest L, Burke T, Phatak H, Souchet T.

    Clin Ther. 2007 Aug;29(8):1671-81.PMID: 17919548 [PubMed - indexed for MEDLINE]Related articles

    6.

    Current lipid management and low cholesterol goal attainment in common daily practice in Spain. The REALITY Study.

    García Ruiz FJ, Marín Ibáñez A, Pérez-Jiménez F, Pintó X, Nocea G, Ahumada C, Alemao E, Yin D; REALITY Study Group.

    Pharmacoeconomics. 2004;22 Suppl 3:1-12.PMID: 15669149 [PubMed - indexed for MEDLINE]Related articles

    7.

    Disparities in lipid management for African Americans and Caucasians with coronary artery disease: a national cross-sectional study.

    Massing MW, Foley KA, Carter-Edwards L, Sueta CA, Alexander CM, Simpson RJ Jr.

    BMC Cardiovasc Disord. 2004 Aug 18;4:15.PMID: 15317654 [PubMed - indexed for MEDLINE]Related articlesFree article

    8.

    Undertreatment of hyperlipidemia in patients with coronary artery disease and heart failure.

    Sueta CA, Massing MW, Chowdhury M, Biggs DP, Simpson RJ Jr.

    J Card Fail. 2003 Feb;9(1):36-41.PMID: 12612871 [PubMed - indexed for MEDLINE]Related articles

    9.

    Is atherosclerosis in diabetes and impaired fasting glucose driven by elevated LDL cholesterol or by decreased HDL cholesterol?

    Drexel H, Aczel S, Marte T, Benzer W, Langer P, Moll W, Saely CH.

    Diabetes Care. 2005 Jan;28(1):101-7.PMID: 15616241 [PubMed - indexed for MEDLINE]Related articlesFree article

    10.

    A long-term follow-up study of serum lipid levels and coronary heart disease in the elderly.

    Li JZ, Chen ML, Wang S, Dong J, Zeng P, Hou LW.

    Chin Med J (Engl). 2004 Feb;117(2):163-7.PMID: 14975195 [PubMed - indexed for MEDLINE]Related articlesFree article

    11.

    Effects of practice setting on quality of lipid-lowering management in patients with coronary artery disease.

    Harnick DJ, Cohen JL, Schechter CB, Fuster V, Smith DA.

    Am J Cardiol. 1998 Jun 15;81(12):1416-20.PMID: 9645890 [PubMed - indexed for MEDLINE]Related articles

    12.

    Joint distribution of non-HDL and LDL cholesterol and coronary heart disease risk prediction among individuals with and without diabetes.

    Liu J, Sempos C, Donahue RP, Dorn J, Trevisan M, Grundy SM.

    Diabetes Care. 2005 Aug;28(8):1916-21.PMID: 16043732 [PubMed - indexed for MEDLINE]Related articlesFree article

    13.

    Beyond low-density lipoprotein: addressing the atherogenic lipid triad in type 2 diabetes mellitus and the metabolic syndrome.

    Nesto RW.

    Am J Cardiovasc Drugs. 2005;5(6):379-87. Review.PMID: 16259526 [PubMed - indexed for MEDLINE]Related articles

    14.
    15.

    What is the consequence of an abnormal lipid profile in patients with type 2 diabetes or the metabolic syndrome?

    Windler E.

    Atheroscler Suppl. 2005 Sep;6(3):11-4. Review.PMID: 16046281 [PubMed - indexed for MEDLINE]Related articles

    16.

    Effects of withdrawal of Xuezhikang, an extract of cholestin, on lipid profile and C-reactive protein: a short-term time course study in patients with coronary artery disease.

    Hu CL, Li YB, Tang YH, Chen JB, Liu J, Tang QZ, Zhang QH, Huang CX.

    Cardiovasc Drugs Ther. 2006 Jun;20(3):185-91.PMID: 16775668 [PubMed - indexed for MEDLINE]Related articles

    17.

    Hyperlipidaemia management after primary coronary artery bypass surgery: a survey of patients and general practitioners.

    Goldsmith I, Lip GY, Emsden K, Nugent A, Patel RL.

    J Cardiovasc Risk. 1999 Aug;6(4):263-7.PMID: 10501279 [PubMed - indexed for MEDLINE]Related articles

    18.

    Lipoprotein subclass measurements by nuclear magnetic resonance spectroscopy improve the prediction of coronary artery disease in Type 1 diabetes. A prospective report from the Pittsburgh Epidemiology of Diabetes Complications Study.

    Soedamah-Muthu SS, Chang YF, Otvos J, Evans RW, Orchard TJ; Pittsburgh Epidemiology of Diabetes Complications Study.

    Diabetologia. 2003 May;46(5):674-82. Epub 2003 May 13.PMID: 12743701 [PubMed - indexed for MEDLINE]Related articles

    19.

    Medical lipid-regulating therapy: current evidence, ongoing trials and future developments.

    Evans M, Roberts A, Davies S, Rees A.

    Drugs. 2004;64(11):1181-96. Review.PMID: 15161326 [PubMed - indexed for MEDLINE]Related articles

    20.

    Effect of lowering LDL cholesterol substantially below currently recommended levels in patients with coronary heart disease and diabetes: the Treating to New Targets (TNT) study.

    Shepherd J, Barter P, Carmena R, Deedwania P, Fruchart JC, Haffner S, Hsia J, Breazna A, LaRosa J, Grundy S, Waters D.

    Diabetes Care. 2006 Jun;29(6):1220-6.PMID: 16731999 [PubMed - indexed for MEDLINE]Related articlesFree article

    Supplemental Content

    Find related data